drugset / Trial / NCT01435928
PEARL Schizophrenia Maintenance
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
Timeline
- Start
- 2011-09
- Primary completion
- 2013-08
- Completion
- 2013-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lurasidone | Small molecule | 40 mg | — |
| Subject | Lurasidone | Small molecule | 80 mg | — |